series-b
Stage
About
Trioar develops next-generation antibody-drug conjugate (ADC) platforms to improve the efficacy and safety of antibody-based cancer therapeutics through proprietary linker-toxin technologies and tumor-targeting strategies.
Explore Trioar's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.